Our data confirmed that the inhibition of mTOR significantly decreased the expression of PD-L1 in patient-derived organoids (n = 9 out of 11 total gastric cancer cases which were positive in both HER2 and PD-L1 as listed in Table 1). Here, ERBB2 is linked to gastric cancer.